[墨西哥科阿韦拉州新冠肺炎患者与死亡相关的临床特征及合并症]
[Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico)].
作者信息
Salinas-Aguirre J E, Sánchez-García C, Rodríguez-Sanchez R, Rodríguez-Muñoz L, Díaz-Castaño A, Bernal-Gómez R
机构信息
Secretaría de Salud del Estado de Coahuila de Zaragoza, Coahuila de Zaragoza, México.
出版信息
Rev Clin Esp. 2022 May;222(5):288-292. doi: 10.1016/j.rce.2020.12.006. Epub 2021 Jan 20.
Abstract
BACKGROUND AND OBJECTIVE
This study aims to describe the characteristics of patients with COVID-19 in a state in northern Mexico and establish the comorbidities associated with mortality.
METHODS
Patients with COVID-19, divided into survivors and non-survivors, were analyzed. The data were analyzed using the chi-square test, Student's t-test, and Cox's regression model.
RESULTS
A total of 17,479 patients were included and mortality rate of 6.3% was reported. Age over 60 years (HR = 8.04; 95% CI 7.03-9.19), diabetes (HR = 1.63; 95% CI 1.40-1.89), high blood pressure (HR = 1.48; 95% CI 1.28-1.72), obesity (HR = 1.37; 95% CI 1.18-1.60) and chronic kidney disease (HR = 2.06; 95% CI 1.64-2.59) were significantly associated with mortality.
CONCLUSIONS
Diabetes, high blood pressure, obesity, and chronic kidney disease increased mortality among patients with COVID-19 in the population of Coahuila, Mexico. The factor that most contributed to risk of death was age over 60 years.
摘要
背景与目的
本研究旨在描述墨西哥北部某州新冠肺炎患者的特征，并确定与死亡率相关的合并症。
方法
对新冠肺炎患者进行分析，分为幸存者和非幸存者。数据采用卡方检验、学生t检验和Cox回归模型进行分析。
结果
共纳入17479例患者，报告死亡率为6.3%。60岁以上（HR = 8.04；95%CI 7.03 - 9.19）、糖尿病（HR = 1.63；95%CI 1.40 - 1.89）、高血压（HR = 1.48；95%CI 1.28 - 1.72）、肥胖（HR = 1.37；95%CI 1.18 - 1.60）和慢性肾脏病（HR = 2.06；95%CI 1.64 - 2.59）与死亡率显著相关。
结论
在墨西哥科阿韦拉州人群中，糖尿病、高血压、肥胖和慢性肾脏病增加了新冠肺炎患者的死亡率。导致死亡风险的最主要因素是60岁以上年龄。
相似文献
1
[Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico)].[墨西哥科阿韦拉州新冠肺炎患者与死亡相关的临床特征及合并症]
Rev Clin Esp. 2022 May;222(5):288-292. doi: 10.1016/j.rce.2020.12.006. Epub 2021 Jan 20.
2
Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico).墨西哥科阿韦拉州 COVID-19 患者死亡的临床特征和合并症。
Rev Clin Esp (Barc). 2022 May;222(5):288-292. doi: 10.1016/j.rceng.2020.12.007. Epub 2021 Oct 5.
3
Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients with COVID-19 in Mexico.高血压、糖尿病和肥胖症是墨西哥 COVID-19 患者死亡的主要危险因素。
Arch Med Res. 2021 May;52(4):443-449. doi: 10.1016/j.arcmed.2020.12.002. Epub 2020 Dec 16.
4
Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study.在加拿大，167500 例 COVID-19 患者中，先前存在的合并症与死亡率和疾病严重程度的关系：一项基于人群的队列研究。
PLoS One. 2021 Oct 5;16(10):e0258154. doi: 10.1371/journal.pone.0258154. eCollection 2021.
5
Risk Factors and Clinical Phenotypes Associated with Severity in Patients with COVID-19 in Northeast Mexico.墨西哥东北部 COVID-19 患者严重程度相关的风险因素和临床表型。
Vector Borne Zoonotic Dis. 2021 Sep;21(9):720-726. doi: 10.1089/vbz.2021.0016. Epub 2021 Jul 13.
6
Obesity is a strong risk factor for short-term mortality and adverse outcomes in Mexican patients with COVID-19: a national observational study.肥胖是墨西哥新冠肺炎患者短期死亡率和不良结局的一个重要风险因素：一项全国性观察性研究。
Epidemiol Infect. 2021 Apr 29;149:e109. doi: 10.1017/S0950268821001023.
7
Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico.墨西哥大型数据集内 COVID-19 患者的临床特征和死亡风险因素。
Ann Epidemiol. 2020 Dec;52:93-98.e2. doi: 10.1016/j.annepidem.2020.08.005. Epub 2020 Aug 14.
8
Comorbidity, poverty and social vulnerability as risk factors for mortality in pregnant women with confirmed SARS-CoV-2 infection: analysis of 13 062 positive pregnancies including 176 maternal deaths in Mexico.合并症、贫困和社会脆弱性是确诊感染 SARS-CoV-2 的孕妇死亡的危险因素：对墨西哥 13062 例阳性妊娠（包括 176 例孕产妇死亡）的分析。
Ultrasound Obstet Gynecol. 2022 Jan;59(1):76-82. doi: 10.1002/uog.24797. Epub 2021 Dec 17.
9
Comparison of COVID-19 survival in relation to CPAP length of treatment and by comorbidity and transmission setting (community or hospital acquired) in a medium-sized UK hospital in 2020: a retrospective study.2020 年英国一家中型医院中与 CPAP 治疗时间长短、合并症以及传播途径（社区获得性或医院获得性）相关的 COVID-19 患者存活率比较：一项回顾性研究。
BMJ Open. 2022 Nov 22;12(11):e060994. doi: 10.1136/bmjopen-2022-060994.
10
Survival analysis and mortality predictors of COVID-19 in a pediatric cohort in Mexico.墨西哥儿科队列中 COVID-19 的生存分析和死亡预测因素。
Front Public Health. 2022 Dec 16;10:969251. doi: 10.3389/fpubh.2022.969251. eCollection 2022.
引用本文的文献
1
Rurality and COVID-19 Outcomes: Unraveling the Impact of Nursing Home Residency Using Bayesian Analysis.农村地区与新冠疫情结果：利用贝叶斯分析揭示养老院居住情况的影响
J Clin Med. 2024 Nov 28;13(23):7244. doi: 10.3390/jcm13237244.
2
Modified Early Warning Score: Clinical Deterioration of Mexican Patients Hospitalized with COVID-19 and Chronic Disease.改良早期预警评分：COVID-19合并慢性病住院的墨西哥患者的临床病情恶化情况
Healthcare (Basel). 2023 Sep 29;11(19):2654. doi: 10.3390/healthcare11192654.
3
Association of Toxoplasmosis and COVID-19 in a MexicanPopulation.墨西哥人群中弓形虫病与新型冠状病毒肺炎的关联
Microorganisms. 2023 May 30;11(6):1441. doi: 10.3390/microorganisms11061441.
4
Lethality risk markers by sex and age-group for COVID-19 in Mexico: a cross-sectional study based on machine learning approach.墨西哥 COVID-19 按性别和年龄组划分的致死风险标志物：基于机器学习方法的横断面研究。
BMC Infect Dis. 2023 Jan 11;23(1):18. doi: 10.1186/s12879-022-07951-w.
5
Assessing the Nationwide COVID-19 Risk in Mexico through the Lens of Comorbidity by an XGBoost-Based Logistic Regression Model.基于 XGBoost 的逻辑回归模型评估墨西哥全国范围内 COVID-19 风险的合并症视角。
Int J Environ Res Public Health. 2022 Sep 22;19(19):11992. doi: 10.3390/ijerph191911992.
6
Intrinsic Exercise Capacity Affects Glycine and Angiotensin-Converting Enzyme 2 (ACE2) Levels in Sedentary and Exercise Trained Rats.内在运动能力影响久坐不动和运动训练大鼠体内的甘氨酸及血管紧张素转换酶2（ACE2）水平。
Metabolites. 2022 Jun 15;12(6):548. doi: 10.3390/metabo12060548.
7
Survival of COVID-19 with Multimorbidity Patients.患有多种疾病的COVID-19患者的生存情况。
Healthcare (Basel). 2021 Oct 22;9(11):1423. doi: 10.3390/healthcare9111423.
本文引用的文献
1
[Epidemiology of COVID-19 in Mexico: from the 27th of February to the 30th of April 2020].[墨西哥2019冠状病毒病流行病学：2020年2月27日至4月30日]
Rev Clin Esp. 2020 Nov;220(8):463-471. doi: 10.1016/j.rce.2020.05.007. Epub 2020 May 27.
2
Comorbidity and its Impact on Patients with COVID-19.合并症及其对COVID-19患者的影响。
SN Compr Clin Med. 2020;2(8):1069-1076. doi: 10.1007/s42399-020-00363-4. Epub 2020 Jun 25.
3
Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico.墨西哥大型数据集内 COVID-19 患者的临床特征和死亡风险因素。
Ann Epidemiol. 2020 Dec;52:93-98.e2. doi: 10.1016/j.annepidem.2020.08.005. Epub 2020 Aug 14.
4
Risk factors for mortality among COVID-19 patients.COVID-19 患者死亡的风险因素。
Diabetes Res Clin Pract. 2020 Aug;166:108293. doi: 10.1016/j.diabres.2020.108293. Epub 2020 Jul 3.
5
IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT.墨西哥新冠病毒检测呈阳性患者中合并症的影响：一项全国队列的回顾性分析
Rev Invest Clin. 2020;72(3):151-158. doi: 10.24875/RIC.20000207.
6
Mortality and survival of COVID-19.COVID-19 的死亡率和生存率。
Epidemiol Infect. 2020 Jun 25;148:e123. doi: 10.1017/S0950268820001405.
7
Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis.感染SARS-CoV2患者的合并症患病率及死亡病例：一项系统评价与荟萃分析。
Rev Inst Med Trop Sao Paulo. 2020 Jun 22;62:e43. doi: 10.1590/S1678-9946202062043. eCollection 2020.
8
Ethnic disparities in COVID-19 mortality: are comorbidities to blame?新冠病毒疾病（COVID-19）死亡率中的种族差异：应归咎于合并症吗？
Lancet. 2020 Jul 4;396(10243):22. doi: 10.1016/S0140-6736(20)31423-9. Epub 2020 Jun 19.
9
[Coronavirus disease 2019 (COVID-19) in Latin America: Role of primary care in preparedness and response].拉丁美洲的2019冠状病毒病（COVID-19）：初级保健在防范与应对中的作用
Aten Primaria. 2020 Jun-Jul;52(6):369-372. doi: 10.1016/j.aprim.2020.04.001. Epub 2020 Apr 17.
10
Association between age and clinical characteristics and outcomes of COVID-19.年龄与 COVID-19 的临床特征和结局的关系。
Eur Respir J. 2020 May 27;55(5). doi: 10.1183/13993003.01112-2020. Print 2020 May.
Zotero 插件